ARMATA PHARMACEUTICALS INC (ARMP) Fundamental Analysis & Valuation

NYSEARCA:ARMP • US04216R1023

Current stock price

9.55 USD
-0.21 (-2.15%)
Last:

This ARMP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ARMP Profitability Analysis

1.1 Basic Checks

  • In the past year ARMP has reported negative net income.
  • In the past year ARMP has reported a negative cash flow from operations.
  • ARMP had negative earnings in each of the past 5 years.
  • ARMP had a negative operating cash flow in each of the past 5 years.
ARMP Yearly Net Income VS EBIT VS OCF VS FCFARMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • ARMP's Return On Assets of -226.06% is on the low side compared to the rest of the industry. ARMP is outperformed by 90.49% of its industry peers.
Industry RankSector Rank
ROA -226.06%
ROE N/A
ROIC N/A
ROA(3y)-106.05%
ROA(5y)-77.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARMP Yearly ROA, ROE, ROICARMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ARMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARMP Yearly Profit, Operating, Gross MarginsARMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. ARMP Health Analysis

2.1 Basic Checks

  • ARMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ARMP has more shares outstanding
  • Compared to 5 years ago, ARMP has more shares outstanding
  • Compared to 1 year ago, ARMP has a worse debt to assets ratio.
ARMP Yearly Shares OutstandingARMP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
ARMP Yearly Total Debt VS Total AssetsARMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -9.66, we must say that ARMP is in the distress zone and has some risk of bankruptcy.
  • ARMP has a worse Altman-Z score (-9.66) than 73.01% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.66
ROIC/WACCN/A
WACC8.96%
ARMP Yearly LT Debt VS Equity VS FCFARMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M

2.3 Liquidity

  • A Current Ratio of 1.19 indicates that ARMP should not have too much problems paying its short term obligations.
  • The Current ratio of ARMP (1.19) is worse than 85.24% of its industry peers.
  • A Quick Ratio of 1.19 indicates that ARMP should not have too much problems paying its short term obligations.
  • ARMP has a Quick ratio of 1.19. This is amonst the worse of the industry: ARMP underperforms 84.66% of its industry peers.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 1.19
ARMP Yearly Current Assets VS Current LiabilitesARMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ARMP Growth Analysis

3.1 Past

  • The earnings per share for ARMP have decreased strongly by -796.15% in the last year.
  • ARMP shows a decrease in Revenue. In the last year, the revenue decreased by -5.22%.
  • ARMP shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 43.00% yearly.
EPS 1Y (TTM)-796.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4771.43%
Revenue 1Y (TTM)-5.22%
Revenue growth 3Y-3.81%
Revenue growth 5Y43%
Sales Q2Q%-12.15%

3.2 Future

  • The Earnings Per Share is expected to grow by 19.86% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 65.50% on average over the next years. This is a very strong growth
EPS Next Y76.14%
EPS Next 2Y31.31%
EPS Next 3Y19.86%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y65.5%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ARMP Yearly Revenue VS EstimatesARMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 2025 2029 2030 2031 2032 2033 100M 200M 300M
ARMP Yearly EPS VS EstimatesARMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -50 -100 -150 -200 -250

More info and screens

Find the best growth stocksShow best growing peers

0

4. ARMP Valuation Analysis

4.1 Price/Earnings Ratio

  • ARMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARMP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARMP Price Earnings VS Forward Price EarningsARMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARMP Per share dataARMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • ARMP's earnings are expected to grow with 19.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.31%
EPS Next 3Y19.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ARMP Dividend Analysis

5.1 Amount

  • ARMP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARMP Fundamentals: All Metrics, Ratios and Statistics

ARMATA PHARMACEUTICALS INC

NYSEARCA:ARMP (4/29/2026, 8:04:00 PM)

9.55

-0.21 (-2.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.66
Industry Growth13.04
Earnings (Last)03-25
Earnings (Next)05-07
Inst Owners3.39%
Inst Owner Change0.05%
Ins Owners0.05%
Ins Owner Change-0.05%
Market Cap349.82M
Revenue(TTM)4.90M
Net Income(TTM)-173.80M
Analysts82.5
Price Target17.85 (86.91%)
Short Float %2.13%
Short Ratio4.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-558.85%
Min EPS beat(2)-1044.96%
Max EPS beat(2)-72.74%
EPS beat(4)1
Avg EPS beat(4)-270.6%
Min EPS beat(4)-1044.96%
Max EPS beat(4)48.4%
EPS beat(8)4
Avg EPS beat(8)-109.73%
EPS beat(12)5
Avg EPS beat(12)-84.82%
EPS beat(16)6
Avg EPS beat(16)-65.99%
Revenue beat(2)1
Avg Revenue beat(2)13.03%
Min Revenue beat(2)-17.68%
Max Revenue beat(2)43.75%
Revenue beat(4)2
Avg Revenue beat(4)3.75%
Min Revenue beat(4)-65.13%
Max Revenue beat(4)54.05%
Revenue beat(8)3
Avg Revenue beat(8)12.82%
Revenue beat(12)5
Avg Revenue beat(12)8.29%
Revenue beat(16)7
Avg Revenue beat(16)7.97%
PT rev (1m)16.67%
PT rev (3m)45.83%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 71.33
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.66
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0.13
BVpS-5.97
TBVpS-6.34
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -226.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-106.05%
ROA(5y)-77.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.4%
Cap/Sales 11.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.19
Quick Ratio 1.19
Altman-Z -9.66
F-Score3
WACC8.96%
ROIC/WACCN/A
Cap/Depr(3y)338.36%
Cap/Depr(5y)274.9%
Cap/Sales(3y)75.73%
Cap/Sales(5y)59.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-796.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4771.43%
EPS Next Y76.14%
EPS Next 2Y31.31%
EPS Next 3Y19.86%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.22%
Revenue growth 3Y-3.81%
Revenue growth 5Y43%
Sales Q2Q%-12.15%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y65.5%
EBIT growth 1Y26.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.39%
OCF growth 3YN/A
OCF growth 5YN/A

ARMATA PHARMACEUTICALS INC / ARMP Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ARMATA PHARMACEUTICALS INC (ARMP) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ARMP.


What is the valuation status for ARMP stock?

ChartMill assigns a valuation rating of 0 / 10 to ARMATA PHARMACEUTICALS INC (ARMP). This can be considered as Overvalued.


Can you provide the profitability details for ARMATA PHARMACEUTICALS INC?

ARMATA PHARMACEUTICALS INC (ARMP) has a profitability rating of 0 / 10.


How sustainable is the dividend of ARMATA PHARMACEUTICALS INC (ARMP) stock?

The dividend rating of ARMATA PHARMACEUTICALS INC (ARMP) is 0 / 10 and the dividend payout ratio is 0%.